The Latest Cardiac and Vascular News
Vantage Galan 3T the First System in the MR Portfolio with Access to Advanced intelligent Clear-IQ Engine (AiCE) TUSTIN, Calif.–(BUSINESS WIRE)–Canon Medical Systems USA, Inc. has received 510(k) clearance on its Advanced intelligent Clear-IQ Engine (AiCE) for the Vantage Galan 3T MR system, further expanding access to its new Deep Learning Reconstruction (DLR) […]
ANN ARBOR, Mich., March 18, 2020 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced the appointment of Alan Fuhrman as a Class III director, with a term expiring at the 2022 meeting of stockholders. “On behalf of the Lipid Management team and our directors, I am very pleased to welcome […]
FAIRWAY, Kan., March 17, 2020 /PRNewswire/ — Artio Medical, a medical device company developing innovative products for peripheral vascular and neurovascular diseases, announced today the recent presentation of interim nonclinical study results at the ABC-WIN Seminar in Val d’Isere, France. Presented by Dr. Blaise Baxter, a neurovascular and peripheral interventional radiologist, the interim data demonstrated […]
SANTA MONICA, Calif.–(BUSINESS WIRE)–Catasys, Inc. (NASDAQ: CATS) (“Catasys” or the “Company”), a leading AI and telehealth enabled, virtualized outpatient healthcare treatment company, today announced the appointment of Mr. Brandon H. LaVerne as Chief Financial Officer. Mr. Terren Peizer, Chairman and CEO of Catasys, stated, “Catasys is rapidly scaling from being the leading […]
Post-Approval Study will evaluate real-world safety and efficacy evidence for breakthrough heart failure therapy MT. LAUREL, N.J.–(BUSINESS WIRE)–Impulse Dynamics, Inc., a company dedicated to improving the lives of people with heart failure, today announced the first enrollment in a post-approval study of its innovative CCM™ therapy delivered by the Optimizer® system. […]
MORRISVILLE, N.C.–(BUSINESS WIRE)–Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or the “Company”), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for […]
HELP study exceeds target enrollment with 37 patients 84% initial open-label lead-in response rate to qualify for randomization Pulmonary capillary wedge pressure (PCWP) was reduced, on average, by 7.5 mmHg during exercise following the initial levosimendan infusion No serious drug-related adverse events have been reported to date Top-line data expected […]
Paragonix SherpaPak™ Cardiac Transport System is the only FDA cleared and CE marked device that safeguards hearts between donor and recipient patients CAMBRIDGE, Mass.–(BUSINESS WIRE)–Paragonix Technologies, Inc. today announced AdventHealth (Orlando, Florida) has adopted its Paragonix SherpaPak™ Cardiac Transport System (CTS) for the preservation of donor hearts for transplantation. A recent […]
The MIT-spinoff commercializing a clinical grade, heart monitoring “Smart Bra” for cardiovascular disease represents the first Femtech investment outside of the reproductive health and breast cancer space CAMBRIDGE, Mass.–(BUSINESS WIRE)–Health technology company Bloomer Tech (Bloomer) today announced that it has raised $3M in a Series Seed funding round. Material Impact, who […]
NEW YORK, March 12, 2020 (GLOBE NEWSWIRE) — Heartbeat Health, a leading digital health company aimed at improving heart health and addressing cardiovascular disease, announced today that it has closed $8.2 million in Series A funding led by .406 Ventures and Optum Ventures, with participation from existing investors Kindred Ventures, Lerer Hippeau, Designer Fund and Max Ventures. “Evolving trends […]
